Turing gets go-ahead for Phase I trial; Oasmia prices downsized IPO;

@FierceBiotech: Merrimack wins expedited FDA OK for pancreatic cancer drug Onivyde. Report | Follow @FierceBiotech

@JohnCFierce: The $NK market cap is down to a meager $873M, debuted at $2.6B -- Still too much? Soon-Shiong magic sparkles not so shiny? | Follow @JohnCFierce

@DamianFierce: So I guess $SHPG's Lumena buyout didn't go so well. Story | More | Follow @DamianFierce

> The FDA signed off on Turing Pharmaceuticals' plan to take its drug for a rare epileptic disorder into Phase I, granting fast-track status to the program. More

> Oasmia Pharmaceutical raised $9 million in an IPO, pricing below its expected range. News

> GlaxoSmithKline ($GSK) CEO Andrew Witty said his company's focus on low-margin therapeutic areas will insulate it from the pricing controversy now raging in the U.S. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Roche notches molecular diagnostics sales win; Veracyte CEO lambastes CMS pricing proposals. Report | Follow @EmilyWFierce

> Congressman to introduce bill banning Bayer's Essure contraceptive device. More

> Swiss scientists reveal miniaturized patient monitoring device for ICU. Story

Pharma News

@FiercePharma: Asia's dengue epidemic highlights race for treatment, vaccine options. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Japan's  says its mAb work with  means a need for a $309M API plant expansion. FiercePharmaManufacturing news | Follow @EricPFierce

@CarlyHFierce: : We did an episode of @FierceBiotech Radio on biopharma's wacky Wednesday. More | Follow @CarlyHFierce

> Novartis wins European recs for a pair of new Cosentyx uses. Item

> Shire's not giving up on target Baxalta, it says amid Q3 beat. Article

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.